EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chemotherapy-Associated Thrombotic Microangiopathy

Abinet M Aklilu iD, Anushree C Shirali iD

Kidney360 · 2023-03 · 4 (3) · 409-422

DOI: 10.34067/kid.0000000000000061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney360, 2023-03. Verfasst von Abinet M Aklilu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut. Hauptthemen laut MEDLINE: Thrombotic Microangiopathies, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thrombotic microangiopathy (TMA) is a syndrome of microangiopathic hemolytic anemia and thrombocytopenia with end-organ dysfunction. Although the advent of plasma exchange, immunosuppression, and complement inhibition has improved morbidity and mortality for primary TMAs, the management of secondary TMAs, particularly drug-induced TMA, remains less clear. TMA related to cancer drugs disrupts the antineoplastic treatment course, increasing the risk of cancer progression. Chemotherapeutic agents such as mitomycin-C, gemcitabine, and platinum-based drugs as well as targeted therapies such as antiangiogenesis agents and proteasome inhibitors have been implicated in oncotherapy-associated TMA. Among TMA subtypes, drug-induced TMA is less well-understood. Treatment generally involves withdrawal of the offending agent and supportive care targeting blood pressure and proteinuria reduction. Immunosuppression and therapeutic plasma exchange have not shown clear benefit. The terminal complement inhibitor, eculizumab, has shown promising results in some cases of chemotherapy-associated TMA including in re-exposure. However, the data are limited, and unlike in primary atypical hemolytic uremic syndrome, the role of complement in the pathogenesis of drug-induced TMA is unclear. Larger multicenter studies and unified definitions are needed to elucidate the extent of the problem and potential treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombotic MicroangiopathiesAntineoplastic AgentsNeoplasmsHumansGemcitabineProteasome Inhibitors

Substanzen

Antineoplastic AgentsGemcitabineProteasome Inhibitors

Autor:innen und Institutionen

  • Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut.

ORCID-Profile: Abinet M Aklilu, Anushree C Shirali

Zitieren

APA

Aklilu, A. M., & Shirali, A. C. (2023). Chemotherapy-Associated Thrombotic Microangiopathy. Kidney360, 4(3), 409-422. https://doi.org/10.34067/kid.0000000000000061

Vancouver

Aklilu AM, Shirali AC. Chemotherapy-Associated Thrombotic Microangiopathy. Kidney360. 2023;4(3):409-422. doi:10.34067/kid.0000000000000061

BibTeX
@article{Aklilu2023,
  author = {Aklilu, Abinet M and Shirali, Anushree C},
  title = {Chemotherapy-Associated Thrombotic Microangiopathy},
  journal = {Kidney360},
  year = {2023},
  volume = {4},
  number = {3},
  pages = {409--422},
  doi = {10.34067/kid.0000000000000061}
}
Kostenlos starten →